期刊文献+

贝那普利联用罗格列酮治疗早期糖尿病肾病 被引量:1

Benazepril Combined with Rosiglitazone in Patients with Earlier Period Diabetic Nephropathy
下载PDF
导出
摘要 目的观察贝那普利联用罗格列酮治疗早期糖尿病肾病(DN)的临床效果。方法将本科64例早期DN患者随机分为联合用药组(34例)和贝那普利单用组(30例)。贝那普利单用组患者予以一般治疗、胰岛素治疗及口服贝那普利。联合用药组联用罗格列酮4 mg/天,共3个月。治疗前后分别测收缩压(SBP)、舒张压(DBP)、总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDLC)、低密度脂蛋白胆固醇(LDLC)、血肌酐(Scr)、尿素氮(BUN)、超敏C反应蛋白(us-CRP)、空腹血糖(FBG)、24 h尿蛋白量(Upr)、尿β2-MG。结果两组患者治疗后FBG、SBP、DBP、TC、TG、LDLC、尿β2-MG与治疗前比较下降显著(P<0.05);联合用药组;中Upr、us-CRP、Scr在治疗后也均有显著下降(P<0.05)。联合用药组;FBG、us-CRP、Scr、Upr、尿β2-MG改善优于对照组(P<0.05)。结论贝那普利联用罗格列酮治疗DN在减少尿蛋白、改善肾功能方面明显优于单用贝那普利,提示两药联用在延缓DN进展可能有协同作用。 Objective To evaluate the clinical efficacy of benazepril combined with rosiglitazone in patients with earlier period diabetic nephropathy ( DN ). Methods 64 patients with earlier period DN were randomly allocated to a therapeutic group ( n = 34 )or a control group ( n = 30 ). Patients in the two groups were given the same regimen, such as common treatment, insulin injection and oral benazepril. The therapeutic group were added with oral rosiglitazone 4 mg daily for 3 months. Before and after treatment, levels of systolic blood pressure ( SBP ), diastolic pressure ( DBP ), total cholesterol ( TC ), triglyeeride ( TG ), high - density lipoprotein cholesterol ( HDLC ), low - density lipoprotein holesterol ( LDL - C ), creatinine ( Scr ), urea nitrogen ( BUN ), high - sensitivity C - reactive protein ( us - CRP ) , fasting blood glucose ( FBG ), 24 h urine protein(Upr) , urine beta2 - MG were detected respectively. Results In both groups, statistically significant differences in levels of FBG, SBP, DBP,TC ,TG, LDLC, urine beta2 -MG were observed before and after treatment ( P 〈 0.05 ). In the treatment group, as compared with the bacia lever, us - CRP, Scr, Upr were decreased ( P 〈 0.05 ) , in the control group,they were decreased,but have no statistically differences; FBG, us -CRP, Scr, Upr, urine β2 -MG were recorded in the therapeutic group as compared with controls ( P 〈 0.05 ). Conclusion Benazepril combined with rosiglitazone in treatment of DN showed better effectiveness in reducing albuminuria and improving renal function than benazepril alone,which suggested that combination of the two drugs can be synergistic against DN development.
出处 《南华大学学报(医学版)》 2009年第1期77-79,共3页 Journal of Nanhua University(Medical Edition)
关键词 糖尿病肾病 贝那普利 罗格列酮 diabetic nephropathy benazepril rosiglitazone
  • 相关文献

参考文献7

  • 1孙书珍,汪翼,刘明花,李倩,田永杰,于永慧.苯那普利对糖尿病大鼠肾脏病变保护作用机制的研究[J].山东大学学报(医学版),2006,44(4):404-409. 被引量:4
  • 2Bakris G, Viberti G, Weston WM, et al. Rosiglitazone reduces urinary albumin excretion in type II diabetes [J]. J HumHypertens, 2003, 17 (1): 7- 12.
  • 3Pistrosch F, Herbrig K, Kindel B, et al. Rosiglitazone improves glomendar hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathyin patients [ J ]. Diabetes, 2005,54 (7) : 2206 -2211.
  • 4Sarafidis PA, Lasaridis AN, Nilsson PM, et al. The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetesmellitus and hypertension [ J ]. Am J Hypertens,2005, 18 (2 Pt 1) : 227 -234.
  • 5Gongidi V, Ring C, Moody M, et al. SPARC -like 1 regulates the terminal phase of radial glia - guided migration in the cerebral cortex[J]. Neuron, 2004, 41 (1) : 57 - 69.
  • 6Law AK, Pencea V, Buck CR, et al. Neurogenesis and neuronalmigration in the neonatal rat forebrain anterior subventricular zone do not require GFAP - positive astrocytes[J]. Dev Biol, 1999, 216 (2) : 622 -634.
  • 7Li HS, Chen JH, WuW, et al. Vertebrate slit, a secreted ligand for the transmembrane protein roundabout, is a repellent for olfactory bulb axons [ J ]. Cell, 1999, 96 (6) : 807 -818.

二级参考文献12

  • 1Border WA,Noble NA.Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy[J].Kidney Int,1998,54:1 390-1 391.
  • 2Gilbert RE,Cox A,Wu LL,et al.Expression of transforming growth factor-betal and type Ⅳ collagen in the renal tubulointerstitium in experimental diabetes:effects of ACE inhibition[J].Diabetes,1998,47:414-422.
  • 3Nakamura T,Takahashi T,Fukui M,et al.Enalapril attenuates increased gene expression of extracellular matrix components in diabetic rats[J].Am Soc Nephrol,1995,5:1 492-1 497.
  • 4Suzuki D,Miyazaki M,Jinde K,et al.In situ hybridization studies of matrix metalloproteinase-3,tissue inhibitor of metalloproteinase-1 and type Ⅳ collagen in diabetic nephropathy[J].Kidney Int,1997,52(1):111-119.
  • 5Mclennan SV,Martell SK,Yue DK.Effects of mesangium glycation on matrix metalloproteinase activities:possible role in diabetic nephropathy[J].Diabetes,2002,51 (9):2 612-2 618.
  • 6Mclennan SV,Kelly DJ,Cox AJ,et al.Decreased matrix degradation in diabetic nephropathy:effects of ACE inhibition on the expression and activities of matrix metalloproteinases[J].Diabetologia,2002,45(2):268-275.
  • 7Alderson NL,Chachich ME,Frizzel N,et al.Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat[J].Diabetologia,2004,47(8):1 385-1 395.
  • 8Allen TJ,Cao Z,Youssef S,et al.Role of angiotensin Ⅱ and bradykinin in experimental diabetic nephropathy.Functional and structural studies[J].Diabetes,1997,46:1 612-1 618.
  • 9Singh R,Alavi N,Singh AK,et al.Role of angiotensin Ⅱ in glucose-induced inhibition of mesangial matrix degradation[J].Diabetes,1999,48:2066-2073.
  • 10Laffel LM,McGill JB,Gans DJ.The beneficial effect of ACE inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria.North America Microalbuminuria Study Group[J].Am Med,1995,99:497-504.

共引文献3

同被引文献4

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部